These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9710942)

  • 21. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
    AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
    Glorioso N; Troffa C; Filigheddu F; Dettori F; Soro A; Parpaglia PP; Collatina S; Pahor M
    Hypertension; 1999 Dec; 34(6):1281-6. PubMed ID: 10601131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diurnal variation of blood ketone bodies in insulin-dependent diabetes mellitus and noninsulin-dependent diabetes mellitus patients: the relationship to serum C-peptide immunoreactivity and free insulin.
    Ubukata E
    Ann Nutr Metab; 1990; 34(6):333-42. PubMed ID: 2076025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.
    Santini SA; Carrozza C; Lulli P; Zuppi C; CarloTonolo G; Musumeci S
    J Atheroscler Thromb; 2003; 10(3):160-4. PubMed ID: 14564085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
    Sebestjen M; Boh M; Keber I
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
    Polidori D; Iijima H; Goda M; Maruyama N; Inagaki N; Crawford PA
    Diabetes Obes Metab; 2018 May; 20(5):1321-1326. PubMed ID: 29341404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Dobs AS; Sarma PS; Schteingart D
    Metabolism; 1993 Sep; 42(9):1146-52. PubMed ID: 8412767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia.
    Saunders E; Ferdinand K; Yellen LG; Tonkon MJ; Krug-Gourley S; Poland M
    J Natl Med Assoc; 2000 Jul; 92(7):319-26. PubMed ID: 10946527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative study of the impact of diet versus pravastatin on color vision in Brodman area 19 detected by computerized chromatic analysis (CARDIOCOLOUR Study)].
    Alcalá A; Morell M; Rius F
    Rev Esp Cardiol; 2002 Dec; 55(12):1243-50. PubMed ID: 12459073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
    Strauss WE; Lapsley D; Gaziano JM
    Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of pravastatin on hepatic cholesterol metabolism].
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    Fortschr Med; 1991 Mar; 109(8):189-94. PubMed ID: 1905265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketonaemia in uncontrolled diabetes mellitus.
    Watkins PJ; Hill DM; Fitzgerald MG; Malins JM
    Br Med J; 1970 Nov; 4(5734):522-5. PubMed ID: 4991729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM.
    Bhatnagar D; Durrington PN; Kumar S; Mackness MI; Dean J; Boulton AJ
    Diabetes; 1995 Apr; 44(4):460-5. PubMed ID: 7698516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of pravastatin on serum cholesterol levels in hypercholesterolemic diabetic rabbits.
    Arbeeny CM; Bergquist KE
    Biochim Biophys Acta; 1991 Apr; 1096(3):238-44. PubMed ID: 1902119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful dissolution of cholesterol gallstone during treatment with pravastatin.
    Smit JW; van Erpecum KJ; Stolk MF; Geerdink RA; Cluysenaer OJ; Erkelens DW; van Berge Henegouwen GP
    Gastroenterology; 1992 Sep; 103(3):1068-70. PubMed ID: 1499908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketone bodies as markers for type 1 (insulin-dependent) diabetes and their value in the monitoring of diabetic control.
    Harano Y; Kosugi K; Hyosu T; Suzuki M; Hidaka H; Kashiwagi A; Uno S; Shigeta Y
    Diabetologia; 1984 May; 26(5):343-8. PubMed ID: 6376243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased ketonaemia in the monosodium glutamate-induced obese rats.
    Nakai T; Tamai T; Takai H; Hayashi S; Fujiwara R; Miyabo S
    Life Sci; 1986 Jun; 38(22):2009-13. PubMed ID: 3713435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.